Cerebrospinal fluid studies of monoamine metabolism in schizophrenia.

No abstract is available for this paper.

• Publication year

  1986

• Venue

  Psychiatric Clinics of North America

• Publication date

  1986-03-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/S0193-953X(18)30636-1PMID 2421272
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phenylethylamine and monoamine metabolites in CSF of schizophrenics: Effects of neuroleptic treatment

  2005cited by this paper
• Effects of the noradrenaline neurotoxin DSP 4 on monoamine neurons and their transmitter turnover in rat CNS

  2005cited by this paper
• Schizophrenia at the crossroads: a blueprint for the 80s.

  1985cited by this paper
• Serotonin and schizophrenia: correlations between serotonergic activity and schizophrenic motor behavior.

  1985cited by this paper
• CSF monoamine metabolites in chronic schizophrenic patients who attempt suicide

  1985cited by this paper
• CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls.

  1984cited by this paper
• Cerebral ventricular size in the offspring of schizophrenic mothers. A preliminary study.

  1984cited by this paper
• Bilateral skin conductance activity, clinical symptoms and CSF monoamine metabolite levels in unmedicated schizophrenics, differing in rate of habituation.

  1984cited by this paper
• CSF 5-hydroxyindoleacetic acid levels in suicidal schizophrenic patients.

  1984cited by this paper
• Lateral ventricular size, psychopathology, and medication response in the psychoses.

  1984cited by this paper
• Impaired noradrenergic transmission in schizophrenia?

  1984cited by this paper
• Association between cerebral ventricular enlargement and suicide attempts in chronic schizophrenia.

  1984cited by this paper
• Spinal fluid monoamine metabolites and anti-cytomegalovirus antibodies and brain scan evaluation in schizophrenia.

  1984cited by this paper
• Family factors in schizophrenic relapse. Replication in California of British research on expressed emotion.

  1984cited by this paper
• Dopamine-beta-hydroxylase activity and homovanillic acid in spinal fluid of schizophrenics with brain atrophy.

  1983cited by this paper
• Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia

  1983cited by this paper
• CSF dopamine beta-hydroxylase in schizophrenia.

  1983cited by this paper
• Childhood psychosis and monoamine metabolites in spinal fluid

  1983cited by this paper
• alpha-Adrenergic receptor function in schizophrenia. Receptor number, cyclic adenosine monophosphate production, adenylate cyclase activity, and effect of drugs.

  1983cited by this paper
• Cerebroventricular size and cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy volunteers.

  1983cited by this paper
• Low CSF 5-hydroxyindoleacetic acid in schizophrenic patients with enlarged cerebral ventricles.

  1983cited by this paper
• Coupling of dopamine D1 recognition sites with adenylate cyclase in nuclei accumbens and caudatus of schizophrenics.

  1983cited by this paper
• Postnatal development of aminergic projections to frontal cortex: Effects of cortical lesions

  1983cited by this paper
• Reliability of norepinephrine and major monoamine metabolite measurements in CSF of schizophrenic patients.

  1983cited by this paper
• Variability and the dopamine hypothesis of schizophrenia.

  1983cited by this paper
• Clinical differences between schizophrenic patients with and without large cerebral ventricles.

  1983cited by this paper
• Cerebrospinal fluid probenecid studies: a reinterpretation.

  1983cited by this paper
• Cerebral glucography with positron tomography. Use in normal subjects and in patients with schizophrenia.

  1982cited by this paper
• Increased brain dopamine and dopamine receptors in schizophrenia.

  1982cited by this paper
• Increased noradrenaline levels in CSF and plasma of schizophrenic patients.

  1982cited by this paper
• Brain catecholamines in schizophrenia — a good case for noradrenaline

  1982cited by this paper
• Cerebral ventricular size in twins discordant for schizophrenia.

  1982cited by this paper
• Cerebrospinal fluid hydroxylase cofactor in schizophrenia.

  1982cited by this paper
• Long-term pimozide pretreatment differentially affects behavioral responses to dextroamphetamine in schizophrenia. Further exploration of the dopamine hypothesis of schizophrenia.

  1982cited by this paper
• CSF monoamine metabolites in schizophrenic patients

  1982cited by this paper
• The effect of pimozide on CSF norepinephrine in schizophrenia.

  1981cited by this paper
• Increased whole blood serotonin concentrations in chronic schizophrenic patients.

  1981cited by this paper
• Familial aspects of CT scan abnormalities in chronic schizophrenic patients.

  1981cited by this paper
• Blood tryptophan metabolism in chronic schizophrenics.

  1981cited by this paper
• Hormones, dopamine receptors and schizophrenia.

  1981cited by this paper
• Cerebrospinal fluid homovanillic acid patterns during neuroleptic treatment.

  1981cited by this paper
• Schizophrenia: elevated cerebrospinal fluid norepinephrine.

  1980cited by this paper
• A comparative uptake study of serotonin, dopamine, and norepinephrine by platelets of acute schizophrenic patients.

  1980cited by this paper
• Molecular pathology of schizophrenia: more than one disease process?

  1980cited by this paper
• CSF monoamine metabolites in depression and schizophrenia.

  1980cited by this paper
• Relationships in Healthy Volunteers Between Concentrations of Monoamine Metabolites in Cerebrospinal Fluid and Family History of Psychiatric Morbidity

  1980cited by this paper
• Noradrenergic Overactivity in Chronic Schizophrenia: Evidence Based on Cerebrospinal Fluid Noradrenaline and Cyclic Nucleotide Concentrations

  1980cited by this paper
• Increased dopamine concentration in limbic areas of brain from patients dying with schizophrenia.

  1979cited by this paper
• Tardive dyskinesia: A clinical test of the supersensitivity hypothesis

  1979cited by this paper
• The dopamine hypothesis of schizophrenia revisited.

  1979cited by this paper
• Monoamine Mechanisms in Chronic Schizophrenia: Post-Mortem Neurochemical Findings

  1979cited by this paper
• Cerebrospinal fluid cyclic AMP and acid monoamine metabolites following probenecid: Studies in psychiatric patients

  1979cited by this paper
• Difficulties in comparing catecholamine-related enzymes from the brains of schizophrenics and controls.

  1978cited by this paper
• Norepinephrine in chronic paranoid schizophrenia: above-normal levels in limbic forebrain.

  1978cited by this paper
• CSF acid monoamine metabolites in psychotic syndromes: what might they signify?

  1978cited by this paper
• Clinical correlates of CSF cyclic nucleotides in schizophrenia.

  1978cited by this paper
• Norepinephrine-dopamine interactions and behavior.

  1977cited by this paper
• Stress-induced growth hormone release: psychologic and physiologic correlates.

  1976cited by this paper
• An examination of baseline and drug-induced levels of cyclic nucleotides in the cerebrospinal fluid of control and psychiatric patients.

  1976cited by this paper
• Central noradrenergic function in man: vanillylmandelic acid in CSF.

  1975cited by this paper
• Serotonin (5HT) systems in psychotic states.

  1975cited by this paper
• Neuroleptics, catecholamines, and psychoses: a study of their interrelations.

  1975cited by this paper
• Cerebrospinal fluid amine metabolites in acute schizophrenia.

  1975cited by this paper
• CLOZAPINE AND HALOPERIDOL IN A SINGLE‐BLIND CROSS‐OVER TRIAL: THERAPEUTIC AND BIOCHEMICAL ASPECTS IN THE TREATMENT OF SCHIZOPHRENIA

  1974cited by this paper
• Central dopamine turnover in schizophrenic syndromes.

  1974cited by this paper
• 5-Hydroxyindoleacetic acid (5 HIAA) and homovanillic acid (HVA) following probenecid in acute psychotic patients treated with phenothiazines

  1973cited by this paper
• The content of 5-hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid of patients with acute schizophrenia.

  1971cited by this paper
• Possible Etiology of Schizophrenia: Progressive Damage to the Noradrenergic Reward System by 6-Hydroxydopamine

  1971cited by this paper
• Cerebrospinal fluid monoamine catabolites in drug-induced extrapyramidal disorders.

  1970cited by this paper
• Acid Metabolites from Monoamines in Cerebrospinal Fluid of Chronic Schizophrenics

  1969cited by this paper
• Concentrations of 5-hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid after treatment with probenecid in patients with Parkinson's disease.

  1968cited by this paper
• 5-hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatric or neurological diseases.

  1966cited by this paper
• Studies on sodium transfer and 5-hydroxyindoles in depressive illness

  1963cited by this paper

• Serotonin and schizophrenia

  2020cites this paper
• Medial septum activation produces opposite effects on dopamine neuron activity in the ventral tegmental area and substantia nigra in MAM vs. normal rats

  2018cites this paper
• Dopamine D2 Receptor as a Cellular Component Controlling Nocturnal Hyperactivities in Drosophila melanogaster

  2013cites this paper
• Psychotic Continuum

  2010cites this paper
• Studies of dopamlne metabolite levels In drug-free schizophrenic patients Study Subjects Compared with Findings

  2005cites this paper
• The role of serotonin in schizophrenia: an overview of the nomenclature, distribution and alterations of serotonin receptors in the central nervous system

  2005cites this paper
• Facilins, a novel class of biological factors that facilitate the aortic response to dopamine and other biogenic amines

  2005cites this paper
• Clozapine pharmacology and tardive dyskinesia

  2004cites this paper
• Biochemical Heterogeneity in Schizophrenia: Implications and Research Strategies of the State Dependency Model

  1995cites this paper
• Peripheral andcentral adrenoceptor modulation ofthe behavioural effects ofclozapine inthepaw test

  1994cites this paper
• Peripheral and central adrenoceptor modulation of the behavioural effects of clozapine in the paw test

  1994cites this paper
• A multidimensional approach to analysis of cerebrospinal fluid biogenic amines in schizophrenia: I. Comparisons with healthy control subjects and neuroleptic-treated/unmedicated pairs analyses.

  1994cites this paper
• Platelet serotonin-2 receptors in schizophrenia: effects of illness and neuroleptic treatment.

  1993cites this paper
• [Neurobiological bases of schizophrenia].

  1993cites this paper
• A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia. With particular reference to drug resistance.

  1993cites this paper
• Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics.

  1993cites this paper
• CSF homovanillic acid in schizotypal personality disorder.

  1993cites this paper
• The Dopamine Hypothesis and Neurophysiology Concepts in Schizophrenia

  1992cites this paper
• The role of adenylate cyclase in neuropsychiatric disease.

  1992cites this paper
• A selective review of biological markers in schizophrenia.

  1991cites this paper
• Evidence for reduced and dysregulated turnover of dopamine in schizophrenia.

  1990cites this paper
• Increased distractibility in schizophrenic patients. Electrophysiologic and behavioral evidence.

  1990cites this paper
• Neurochemical measurements in the brains of mice infected with Trypanosoma brucei brucei (TREU 667).

  1989cites this paper
• The role of serotonin in schizophrenia.

  1988cites this paper
• Startle habituation and sensorimotor gating in schizophrenia and related animal models.

  1987cites this paper